Piramal Pharma Board of Directors

Get the latest insights into the leadership at Piramal Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mrs. Nandini Piramal Chairperson
Mr. Peter DeYoung Executive Director
Mr. Vivek Valsaraj Executive Director & CFO
Mr. Nathalie Leitch Non Executive Director
Mr. S Ramadorai Independent Director
Mr. Peter Stevenson Independent Director
Ms. Vibha Paul Rishi Independent Director
Mr. Jairaj Purandare Independent Director
Mr. Sridhar Gorthi Independent Director

Piramal Pharma Share price

PPLPHARMA

198.98

2.18 (-1.08%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:54 IST
BUYSELL
Today's High

203.50

Today's Low

197.20

52 Week Low

181.73

52 Week High

307.90

The current prices are delayed, login to your account for live prices

Piramal Pharma FAQs

The board at Piramal Pharma consists of experienced professionals, including Mrs. Nandini Piramal , Mr. Peter DeYoung , and others, overseeing the company’s strategic and corporate governance.

Directors at Piramal Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mrs. Nandini Piramal is the current chairman at Piramal Pharma.

Executive directors at Piramal Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Piramal Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Piramal Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.